Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: Lab Invest. 2021 Nov 20;102(2):185–193. doi: 10.1038/s41374-021-00700-8

Fig. 3. In vivo therapeutic efficacy of tazemetostat in PDOX models of childhood brain tumors.

Fig. 3

SCID mice were implanted with xenograft cells from the four models, IC-L1115ATRT (A), IC-2305GBM (B), group 3 (ICb-1572MB) (C) and group 4 (ICb-1078MB) (D) MBs, were allowed to grow for 14 days to form solid intra-cerebral (IC) or intra-cerebellar (ICb) xenograft tumors before being treated with tazemetostat alone and in combinations with chemo- and/or radiation as highlighted in the figures. Kaplan-Meier estimate of median time-to-event, ratio in median time to event between the treated and control groups (EFS T/C), and EFS p values were calculated and compared between the treatment groups.